Welcome to Spyre Therapeutics, Inc. Blog Exciting Updates from Spyre Therapeutics Continuing its journey towards expected milestones, Spyre Therapeutics has exciting news to share with its audience. The company’s SPY001 is on-track for interim Phase 1 data by year-end 2024, while SPY002 is set to initiate first-in-human trials in the fourth quarter of the same…
The banking sector sees massive share price gains following Donald Trump’s 2024 presidential election win What does this mean for the banking industry? After Donald Trump secured his second term as President of the United States in the 2024 election, the banking sector experienced significant gains in share prices. Major banks such as JPMorgan and…
Exciting Transformation for Raadr, Inc. as it Rebrands to Telvantis NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Raadr, Inc. (OTC Pink:RDAR) (“Raadr” or the “Company”) a leading provider of advanced technology solutions for the telecommunications industry, is pleased to announce an exciting transformation as it unveils a new name and brand identity,…
The heavy selling pressure might have exhausted for Best Buy (BBY) Is Best Buy (BBY) ready for a trend reversal? Best Buy (BBY) has been under significant selling pressure in recent weeks, causing the stock to be technically oversold. However, this may be coming to an end as there are signs that the stock is…
Unwrap the Best Deals of the Season with RetailMeNot’s Annual Holiday Cash Back Day – November 7-9! Prepare for the Biggest Savings Event of the Year Are you ready to kick off the holiday shopping season in style? Get ready for RetailMeNot’s Annual Holiday Cash Back Day, happening from November 7-9! For the second year…
Franklin Covey Co. (NYSE:FC) Q4 2024 Results Conference Call Summary Key Speakers and Participants Company Participants Derek Hatch – Corporate Controller Paul Walker – Chief Executive Officer Steve Young – Chief Financial Officer Jennifer Colosimo – President, Enterprise Division Sean Covey – President, Education Division Conference Call Participants Jeff Martin – ROTH Capital Partners Samir…
Howmet Aerospace’s Impressive Q3 Earnings Performance Beating EPS Consensus and Outperforming the Market Howmet Aerospace has once again showcased its financial prowess in the third quarter, surpassing expectations and delivering exceptional returns to investors. With a staggering 135.7% return since my initial buy rating, the company has outperformed the S&P 500’s 35.8% return, solidifying its…
PharmAla Biotech Holdings Inc. Enters into Contract to Supply MDMA for Clinical Trial at Yale University TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF) A Step Forward in Research and Development PharmAla Biotech Holdings Inc., a leading biotechnology company specializing in the research, development,…
